AACR In Review: IDO Pushes Ahead, CTLA-4 Combo Lags Behind

Though momentum is building for IDO/PD-1 combos, it's still early days for new immunotherapy programs. Clinicians and investors weigh in on the latest data from the American Association for Cancer Research meeting and the state of the immuno-oncology field.